These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35542432)

  • 1. Discovery of VEGFR2 inhibitors by integrating naïve Bayesian classification, molecular docking and drug screening approaches.
    Kang D; Pang X; Lian W; Xu L; Wang J; Jia H; Zhang B; Liu AL; Du GH
    RSC Adv; 2018 Jan; 8(10):5286-5297. PubMed ID: 35542432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.
    Rathi E; Kumar A; Kini SG
    J Recept Signal Transduct Res; 2019; 39(5-6):415-433. PubMed ID: 31755336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening of cytochrome P450 3A4 inhibitors
    Pang X; Zhang B; Mu G; Xia J; Xiang Q; Zhao X; Liu A; Du G; Cui Y
    RSC Adv; 2018 Oct; 8(61):34783-34792. PubMed ID: 35547066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.
    Sangande F; Julianti E; Tjahjono DH
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reveal the interaction mechanism of five old drugs targeting VEGFR2 through computational simulations.
    Lv Y; Wang Y; Zheng X; Liang G
    J Mol Graph Model; 2020 May; 96():107538. PubMed ID: 31981898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in structure-based drug design and virtual screening of VEGFR tyrosine kinase inhibitors.
    Hoi PM; Li S; Vong CT; Tseng HH; Kwan YW; Lee SM
    Methods; 2015 Jan; 71():85-91. PubMed ID: 25239735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel dual VEGFR2 and Src inhibitors using a multistep virtual screening approach.
    Chen S; Qin C; Sin JE; Yang X; Tao L; Zeng X; Zhang P; Gao CM; Jiang YY; Zhang C; Chen YZ; Chui WK
    Future Med Chem; 2017 Jan; 9(1):7-24. PubMed ID: 27995811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictions of BuChE inhibitors using support vector machine and naive Bayesian classification techniques in drug discovery.
    Fang J; Yang R; Gao L; Zhou D; Yang S; Liu AL; Du GH
    J Chem Inf Model; 2013 Nov; 53(11):3009-20. PubMed ID: 24144102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of machine learning modeling, virtual screening, molecular docking, and molecular dynamics simulations to identify potential VEGFR2 kinase inhibitors.
    Salimi A; Lim JH; Jang JH; Lee JY
    Sci Rep; 2022 Nov; 12(1):18825. PubMed ID: 36335233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rutacecarpine Inhibits Angiogenesis by Targeting the VEGFR2 and VEGFR2-Mediated Akt/mTOR/p70s6k Signaling Pathway.
    Ji L; Wu M; Li Z
    Molecules; 2018 Aug; 23(8):. PubMed ID: 30111763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virtual Screening Strategy Combined Bayesian Classification Model, Molecular Docking for Acetyl-CoA Carboxylases Inhibitors.
    Zhou WN; Zhang YM; Qiao X; Pan J; Yin LF; Zhu L; Zhao JN; Lu S; Lu T; Chen YD; Liu HC
    Curr Comput Aided Drug Des; 2019; 15(3):193-205. PubMed ID: 30411690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, in vitro anticancer activity and in silico studies of certain isoxazole-based carboxamides, ureates, and hydrazones as potential inhibitors of VEGFR2.
    Abou-Seri SM; Eissa AAM; Behery MGM; Omar FA
    Bioorg Chem; 2021 Nov; 116():105334. PubMed ID: 34534755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and Validation of VEGFR2 Kinase as a Target of Voacangine by a Systematic Combination of DARTS and MSI.
    Kim Y; Sugihara Y; Kim TY; Cho SM; Kim JY; Lee JY; Yoo JS; Song D; Han G; Rezeli M; Welinder C; Appelqvist R; Marko-Varga G; Kwon HJ
    Biomolecules; 2020 Mar; 10(4):. PubMed ID: 32230857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 4,6-Disubstituted Pyrimidine Derivatives as Novel Dual VEGFR2/FGFR1 Inhibitors.
    Zhang JY; Xue WJ; Wang M; Li W; Dong R; Li MT; Sun LP
    Chem Biodivers; 2021 May; 18(5):e2100095. PubMed ID: 33829649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of new 4-alkoxyquinazoline-based derivatives as potent VEGFR2 inhibitors.
    Yin Y; Sha S; Wang YT; Wu X; Wang SF; Qiao F; Lv PC; Zhu HL
    Chem Biol Drug Des; 2015 Nov; 86(5):1323-9. PubMed ID: 26032487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating Ligand and Target-Driven Based Virtual Screening Approaches With
    Tutumlu G; Dogan B; Avsar T; Orhan MD; Calis S; Durdagi S
    Front Chem; 2020; 8():167. PubMed ID: 32328476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-Based Virtual Screening for the Identification of High Affinity Compounds as Potent VEGFR2 Inhibitors for the Treatment of Renal Cell Carcinoma.
    Sharma K; Patidar K; Ali MA; Patil P; Goud H; Hussain T; Nayarisseri A; Singh SK
    Curr Top Med Chem; 2018; 18(25):2174-2185. PubMed ID: 30499413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of differences in the VEGFR2 inhibitory activities between semaxanib and SU5205 using 3D-QSAR, docking, and molecular dynamics simulations.
    Muñoz C; Adasme F; Alzate-Morales JH; Vergara-Jaque A; Kniess T; Caballero J
    J Mol Graph Model; 2012 Feb; 32():39-48. PubMed ID: 22070999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing an ensemble docking-based virtual screening strategy for kinase targets by considering protein flexibility.
    Tian S; Sun H; Pan P; Li D; Zhen X; Li Y; Hou T
    J Chem Inf Model; 2014 Oct; 54(10):2664-79. PubMed ID: 25233367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel human Ab against vascular endothelial growth factor receptor 2 shows therapeutic potential for leukemia and prostate cancer.
    Lu RM; Chiu CY; Liu IJ; Chang YL; Liu YJ; Wu HC
    Cancer Sci; 2019 Dec; 110(12):3773-3787. PubMed ID: 31578782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.